Meeting
2018 Gastrointestinal Cancers Symposium
A phase I fixed-dose feasibility study of MK615 and gemcitabine in patients with advanced or metastatic pancreatic cancer.
Authors
Ichiro Moriyama
Shimane University Hospital, Izumo, Japan
Ichiro Moriyama , Fumiyoshi Ikejiri , Koshi Kawakami , Masaya Inoue , Satoshi Kumanomido , Matsuda Shinichiro , Fumimasa Takahashi , Shunsuke Ito , Yusuke Okada , Hiroshi Mochida , Yasumasa Shimazaki , Norimi Ugata , Takahiro Okada , Yumi Jo , Chie Onishi , Tsutomu Takahashi , Takaaki Miyake , Ritsuro Suzuki , Junji Suzumiya
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Sub Track
Multidisciplinary Treatment
Citation
J Clin Oncol 36, 2018 (suppl 4S; abstr 510)
DOI
10.1200/JCO.2018.36.4_suppl.510
Abstract #
510
Poster Bd #
P10
Abstract Disclosures
Similar Posters
Poster
2015 Gastrointestinal Cancers Symposium
FOLFIRINOX for the treatment of advanced pancreatic cancer: U.K. West Midlands experience.
First Author: Ankit Jain
Poster
2018 ASCO Quality Care Symposium
Treatment patterns, toxicity, and outcomes of elderly patients with advanced pancreatic cancer receiving first-line chemotherapy.
First Author: Robert Kudlovich
Poster
2017 Gastrointestinal Cancers Symposium
Gemcitabine and S-1 as first-line chemotherapy in patients with metastatic or advanced pancreatic cancer.
First Author: Weijia Fang
Poster
2017 Gastrointestinal Cancers Symposium
Efficacy of chemotherapy in patients with recurrent pancreatic cancer.
First Author: Akihiro Ohba